RIGL Financial Facts
General and administrative: 4.56MTotal costs and expenses: 26.5M
See Full Income Statement
Total current assets: 86.55M
Accumulated other comprehensive income (loss): 9K
See Full Balance Sheet
Rigel Pharmaceuticals, Inc. (RIGL) Earnings
|
Expand Research on RIGL
| Next EPS Date | 11/10/26 | EPS Growth Rate | -34.9% |
|---|---|---|---|
| Average EPS % Beat Rate | +79.8% | Revenue Growth Rate | +15.2% |
| Average % Move 1-Wk after EPS | +8.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/10/26  |
Q326 | N/A | $0.95 | N/A | N/A | $79.99M | = | N/A | N/A | ||
| 8/4/26 | Q226 | $0.88 | $0.21 | +$0.67 | $78.7M | $54.94M | = |  | | Details | |
| 5/5/26 | Q126 | $0.44 | $0.00 | +$0.44 | $58.8M | N/A | = | | | Details | |
| 3/3/26 | Q425 | $13.54 | $0.00 | +$13.54 | $69.8M | N/A | = | | | Details | |
| 11/4/25 |
Q325 | N/A | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 11/4/25 | Q325 | $1.46 | $0.00 | +$1.46 | $69.46M | N/A | N/A | | | Details | |
| 5/6/25 | Q125 | $0.63 | $0.00 | +$0.63 | $53.33M | N/A | N/A | | | Details | |
| 3/4/25 | Q424 | $0.80 | $0.00 | +$0.80 | $57.6M | N/A | N/A | | | Details |
